undamentalytics Newsletter
Sign in

Altimmune, Inc. revenue

Altimmune, Inc.'s revenue was $41,000 in fiscal 2025, up 105.0% on the year before. Since fiscal 2010 ($21.0m) it has grown at a compound -43.3% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue212431110684−0000
Growth on the year before—+15.6%−86.7%+231.8%−3.8%−43.8%+41.1%−46.1%−101.5%—−95.3%+105.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Altimmune, Inc. $41,000 105.0% —
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%

Compare with peers

Head to head: ALT vs LYELAIM vs ALTALT vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Altimmune, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Altimmune, Inc.